Reuters logo
6 个月内
BRIEF-Celgene reports positive results from Phase III sunbeam trial of oral ozanimod in patients with relapsing multiple sclerosis
2017年2月17日 / 下午1点45分 / 6 个月内

BRIEF-Celgene reports positive results from Phase III sunbeam trial of oral ozanimod in patients with relapsing multiple sclerosis

1 分钟阅读

Feb 17 (Reuters) - Celgene Corp

* Celgene announces positive results from Phase III sunbeam trial of oral ozanimod in patients with relapsing multiple sclerosis

* Celgene Corp - safety and tolerability consistent with phase ii studies

* Celgene Corp - study met its primary endpoint in reducing annualized relapse rate (arr) and measured secondary endpoints, compared to interferon (ifn) β-1a (avonex(reg))

* Says study met its primary endpoint

* Celgene corp - confirmatory Phase III radiance trial data expected in q2 of 2017 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below